| miR-210 |
Serum |
Overexpression of serum miR-210 levels in RCC patients compared to healthy donors. The AUC was 0.77 (95% confidence interval, 0.65–0.89) and the sensitivity and specificity was 65% and 83%, respectively.
|
[90] |
miR-210
miR-1233 |
Serum |
Higher level of serum miR-210 and miR-1233 in ccRCC patients compared to controls. miR-210: the AUC was 0.69 (95% confidence interval, 0.61–0.77) and the sensitivity and specificity was 70% and 62,2%, respectively. miR-1233: the AUC was 0.82 (95% confidence interval, 0.75–0.89) and the sensitivity and specificity was 81% and 76%, respectively.
|
[91] |
miR-210
miR-155 |
Serum |
Higher level of serum miR-210 and miR-155 levels in patients with ccRCC than in healthy controls (HCs). Furthermore, only exosomal miR-210 showed a significant upregulation in patients with ccRCC vs. HCs. miR-210: the AUC was 0.87 (95% confidence interval, 0.79–0.95) and the sensitivity and specificity was 82.5% and 80%, respectively.
|
[92] |
miR-122-5p
miR-206 |
Serum |
High level of miR-122-5p and miR-206, respectively, in metastasized ccRCC and in advanced pT-stage ccRCC. miR-206: the AUC was 0.73 (95% confidence interval, 0.616–0.849) and the sensitivity and specificity was 57.1% and 83.8%, respectively.
|
[94] |
miR-221
miR-222 |
Plasma |
High level of circulating miR-221 and miR-222 compared to healthy individuals. High level of miR-221 in patients with metastasis compared to individuals without metastasis. Correlation between high expression of miR-221 and low overall survival. miR-221: the AUC was 0.696 (95% confidence interval, 0.499-0.893) and the sensitivity and specificity was 72.5% and 33.3%, respectively.
|
[95] |
miR-193a-3p
miR-362
miR-572
miR-28-5p
miR-378 |
Serum |
This 5-miRNA panel showed a high level in the stage I and stage IV groups compared with the noncancer controls. The AUCs for the combination of the 5 miRNAs were 0.801 (95% CI, 0.731–0.871) and 0.797 (95% CI, 0.732–0.863) for stage I and stage I–II cases, respectively, with high sensitivity and specificity. Association of these miRNAs with overall survival.
|
[96] |
miR-190b
miR 26a-1-3p
miR-let-7i-5p
miR-615-3p
miR-200-3p
miR-9-5p |
Plasma |
Kaplan–Meier analysis confirmed the significant association of miR-let-7i-5p (95% CI, 0.21-0.84), miR-26a-1-3p (95% CI, 0.10-0.84), and miR -615-3p (95% CI = 0.11-0.54) with OS. The association of miR-9-5p and miR-190 with OS was not statistically significant.
|
[98] |
miR-210-3p
miR-21-5p
miR185-5p
miR-221-3p
miR-145-5p |
Urine |
Upregulation of miR-21-5p, miR-210-3p, and miR-221-3p in ccRCC fresh frozen tissues compared to matched normal counterparts, while miR-185-5p and miR-145-5p did not show modulation. Upregulation of miR-210-3p in ccRCC urine compared to healthy controls. Reduction of miR-210-3p in the ccRCC samples after surgery in the follow up study.
|
[100] |
miR-122
miR-1271
miR-15b |
Urine |
High and significant level of miR-122, miR-1271, and miR-15b in the ccRCC urine specimens compared to control groups. The AUC for the combination of the 3 miRNAs was 0.96 (95% confidence interval, 0.88-1.04) and the sensitivity and specificity were 100% and 86%, respectively.
|
[101] |
| miR-30c-5p |
Urine |
Low expression of miR-30c-5p in ccRCC patients compared to controls. The AUC was 0.8192 (95% confidence interval, 0.7388-0.8996) and the sensitivity and specificity was 68.57% and 100%, respectively.
|
[102] |
| miR-30a-5pme
|
Urine |
Significantly higher miR-30a-5pme levels in urine from ccRCC patients compared to asymptomatic controls. The AUC was 0.6837 (95% confidence interval, 0.5837-0.7837) and the sensitivity and specificity was 83% and 53%, respectively. Different expression of miR-30a-5pme levels in urine between metastatic and non-metastatic ccRCC. The AUC was 0.7884 (95% confidence interval, 0.5505-0.8601) and the sensitivity and specificity was 80% and 71%, respectively.
|
[103] |
